Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
February 26, 2020
- Takeda’s ALK Drug Alunbrig Gets FDA’s Priority Status for Frontline NSCLC
February 26, 2020
- Shionogi’s Antibiotic Fetroja Now Available in US
February 26, 2020
- Kissei Takes Over Distribution of Desmopressin Brands from Ferring in Japan
February 26, 2020
- Eisai Obtains China Rights for Fuji Yakuhin's Gout Treatment Dotinurad
February 26, 2020
- Non-Japanese Players Nab 60% of Top 20 Company Sales, IQVIA Data Show
February 25, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Takeda Vaults to 9th in Global Pharma Ranking after Shire Buy, Roche Tops List: Jiho Tally
February 21, 2020
- Kyowa Kirin Initiates Japan PI Trial of Automated Injection Device for G-Lasta
February 21, 2020
- GSK Japan Resurrects “Sales” for Rep Performance Review, Doctor Payments; Critics Say It’s a Rollback
February 20, 2020
- Kowa Launches Japan PIII Study of Glanatec/Brimonidine Combo for Glaucoma, Ocular Hypertension
February 20, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
- Japan Pharma Market Logs 1st Growth in 3 Years in 2019, Keytruda Is the Best-Seller: IQVIA
February 19, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Dovobet Foam Formulation Filed in Japan: LEO Pharma/Kyowa Kirin
February 17, 2020
- Tecentriq-Avastin Combo Filed for HCC in Japan: Chugai
February 17, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…